Mode
Text Size
Log in / Sign up

Acute Decompensated Heart Failure

Part of Heart Failure

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acute Decompensated Heart Failure

9 trials tracked for Acute Decompensated Heart Failure: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 599 citations.

9Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 2 Other / NA 4
  1. Phase 4 Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Completed · 599 cited
  2. Phase 4 Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy Completed
  3. Phase 3 Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure Completed
  4. Phase 2 The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure Completed
  5. Phase 2 Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Completed
  6. N/A REducing 30-day ADMIssions in posT-discharge Subjects (READMIT) Completed
Show 3 more trials
  1. N/A Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) Completed
  2. N/A A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients Completed
  3. N/A Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Acute Decompensated Heart Failure: what the trials found

Clinical investigations have evaluated various pharmacological interventions for patients with heart failure. Acetazolamide was studied as an intervention in this patient population 2. Additionally, Nesiritide has been investigated in the context of heart failure management 3.

A large-scale trial assessed the impact of Aliskiren on outcomes including cardiovascular death or heart failure re-hospitalization within 6 and 12 months. The study reported specific counts of these events across different groups, with the clinical summary score showing consistent changes from baseline at 1, 6, and 12 months 4.

Recent results — preliminary, needs further review

  • Diuretic administration was associated with total urine sodium outputs of 1082 and 423 (p<0.001). The incidence of clinically significant acute kidney injury, severe electrolyte abnormality, symptomatic hypotension, or hypertensive emergency did not differ significantly between groups (p=0.43) 1.

For the clinician treating this condition

  • Acetazolamide and Nesiritide are established interventions investigated in heart failure populations [2, 3].
  • Aliskiren was evaluated for its impact on cardiovascular death and re-hospitalization rates over a 12-month period 4.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Heart Failure

Related studies from across the Heart Failure family.

Moderate mitral regurgitation associated with higher risk of primary outcome in HFrEF patients
Cardiology RCT
Moderate mitral regurgitation associated with higher risk of primary outcome in HFrEF patients Trial shows moderate mitral regurgitation impacts heart failure outcomes
This randomized controlled trial of 8232 patients with heart failure and reduced ejection fraction (HFrEF) evaluated the impact of mitral re…
New research identifies that patients with moderate mitral regurgitation may face higher risks in heart failure treatment outcomes.
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing
Cardiology Meta-analysis
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing New Prediction Models Help Identify Heart Failure Risk in Diabetes
This meta-analysis of 65 studies evaluated prediction models for incident heart failure and heart failure hospitalization in people with typ…
New prediction models show promise in identifying heart failure risks for people living with type 2 diabetes.
Heart transplantation provides feasible treatment with favorable long-term survival for end-stage Chagas heart disease
Cardiology Meta-analysis
Heart transplantation provides feasible treatment with favorable long-term survival for end-stage Chagas heart disease Heart transplant offers long term survival for Chagas heart disease
This meta-analysis of 305 patients evaluates outcomes in Chagas heart disease transplant recipients. The analysis indicates that heart trans…
Heart transplants provide a viable path to long term survival for patients with advanced Chagas heart disease.
Nursing-led strategies address patient, systemic, and socio-cultural barriers to cardiac rehabilitation participation
Cardiology Meta-analysis
Nursing-led strategies address patient, systemic, and socio-cultural barriers to cardiac rehabilitation participation Nurses help heart failure patients overcome barriers to cardiac rehab
This systematic review of 17 studies identifies nursing-led interventions as key facilitators for overcoming barriers to cardiac rehabilitat…
Many heart failure patients struggle to join rehab due to fear or travel issues, but nurse-led support can help them stay on track.
Dapagliflozin associated with lower risk of heart failure in frail patients with aortic stenosis
Cardiology RCT
Dapagliflozin associated with lower risk of heart failure in frail patients with aortic stenosis Trial shows dapagliflozin may help frail patients with aortic stenosis
This post hoc analysis examined the impact of dapagliflozin on patients with severe aortic stenosis undergoing transcatheter aortic valve im…
A new analysis suggests the medication dapagliflozin may offer specific benefits for patients with aortic stenosis who are also experiencing…
Cardiac resynchronization therapy increases left ventricular ejection fraction by 9.95% in cancer-related heart failure
Oncology Meta-analysis
Cardiac resynchronization therapy increases left ventricular ejection fraction by 9.95% in cancer-related heart failure Heart therapy shows promise for cancer patients with heart damage
This meta-analysis of 110 patients with cancer therapy-related cardiac dysfunction found that cardiac resynchronization therapy (CRT) increa…
A new look at heart treatments shows that a specific device can improve heart function for cancer survivors with heart damage.
Individualized mechanical circulatory support is necessary as increased hemodynamic support does not uniformly improve survival
Cardiology Sys. Review
Individualized mechanical circulatory support is necessary as increased hemodynamic support does not uniformly improve survival Mechanical Support for Cardiogenic Shock Does Not Uniformly Improve Survival
This mini review examines the role of short-term mechanical circulatory support (MCS) in patients with cardiogenic shock, including those wi…
Newer reviews suggest that while mechanical support helps heart function, it does not always lead to better survival rates for patients in c…
Qili Qiangxin plus conventional medicine improves surrogate markers in heart failure after myocardial infarction
Drug Pipeline Meta-analysis
Qili Qiangxin plus conventional medicine improves surrogate markers in heart failure after myocardial infarction Qili Qiangxin May Improve Heart Function After Heart Attack
This meta-analysis of 1391 patients found that Qili Qiangxin combined with conventional Western medicine led to greater reductions in NT-pro…
Adding Qili Qiangxin to standard medicine may improve heart function and quality of life for patients following a heart attack.
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions
Drug Pipeline Sys. Review
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions RAAS Inhibitors May Protect Organs Beyond Lowering Blood Pressure
This systematic review synthesizes the roles of ACEI, ARB, DRI, ARNI, and MRA in modulating inflammatory responses and oxidative stress. The…
New research suggests certain blood pressure medications may protect the heart, kidneys, and lungs by reducing inflammation and oxidative st…
An RV-first framework addresses controversies in tricuspid intervention and right ventricular support for cardiogenic shock
Cardiology Sys. Review
An RV-first framework addresses controversies in tricuspid intervention and right ventricular support for cardiogenic shock New framework aims to improve care for heart failure patients
This narrative review explores the role of transcatheter tricuspid interventions and mechanical circulatory support for patients with advanc…
Doctors are looking for better ways to treat heart failure and cardiogenic shock using a new approach to manage the right side of the heart.
SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes SGLT2 inhibitors and GLP-1RAs both improve heart failure outcomes
This network meta-analysis of 13,886 patients with type 2 diabetes and heart failure found that both SGLT-2is and GLP-1RAs significantly red…
New data shows both SGLT2 inhibitors and GLP-1RAs effectively reduce heart failure risks for people with type 2 diabetes.
Ventricular Arterial Coupling Surrogates Predict Mortality and Adverse Events in Acute Heart Failure
Cardiology Meta-analysis
Ventricular Arterial Coupling Surrogates Predict Mortality and Adverse Events in Acute Heart Failure Ventricular-arterial coupling measures help identify high risk in heart failure
Meta-analysis of 36,989 patients reveals that RV-PA uncoupling predicts mortality while LV-Ao uncoupling identifies risk for in-hospital car…
New data shows that specific heart measurements can help doctors identify which heart failure patients face the highest risk of death or com…

Questions about Acute Decompensated Heart Failure

Does furosemide plus hypertonic saline lower biomarker levels in acute decompensated heart failure?

Yes, furosemide plus hypertonic saline is linked to lower increases in biomarkers like NT-proBNP, IL-6, and sST2 after a saline load in ADHF patients, though baseline reductions may be similar.

Full answer →
Can natriuresis-guided protocols help with weight loss in acute decompensated heart failure?

Yes, natriuresis-guided protocols increase weight loss in acute decompensated heart failure, with a meta-analysis showing about 0.45 kg more weight loss at 48 hours compared to standard care.

Full answer →
Does a natriuresis-guided diuretic protocol shorten hospital stays for acute decompensated heart failure?

Evidence is mixed: one meta-analysis found natriuresis-guided protocols shortened hospital stays by about 1 day, but another found no significant difference.

Full answer →